-+ 0.00%
-+ 0.00%
-+ 0.00%

When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Turn A Profit?

Simply Wall St·11/17/2026 11:11:35
Listen to the news

Outlook Therapeutics, Inc. (NASDAQ:OTLK) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. The US$96m market-cap company’s loss lessened since it announced a US$62m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$61m, as it approaches breakeven. The most pressing concern for investors is Outlook Therapeutics' path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

Consensus from 4 of the American Biotechs analysts is that Outlook Therapeutics is on the verge of breakeven. They anticipate the company to incur a final loss in 2027, before generating positive profits of US$21m in 2028. So, the company is predicted to breakeven approximately 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2028? Working backwards from analyst estimates, it turns out that they expect the company to grow 56% year-on-year, on average, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

earnings-per-share-growth
NasdaqCM:OTLK Earnings Per Share Growth November 17th 2026

Given this is a high-level overview, we won’t go into details of Outlook Therapeutics' upcoming projects, however, bear in mind that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

View our latest analysis for Outlook Therapeutics

One thing we would like to bring into light with Outlook Therapeutics is it currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

There are too many aspects of Outlook Therapeutics to cover in one brief article, but the key fundamentals for the company can all be found in one place – Outlook Therapeutics' company page on Simply Wall St. We've also put together a list of important aspects you should further research:

  1. Valuation: What is Outlook Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Outlook Therapeutics is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Outlook Therapeutics’s board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.